Format
Sort by
Items per page

Send to

Choose Destination

Best matches for senicapoc:

Search results

Items: 1 to 20 of 52

1.

Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.

Lozano-Gerona J, Oliván-Viguera A, Delgado-Wicke P, Singh V, Brown BM, Tapia-Casellas E, Pueyo E, Valero MS, Garcia-Otín ÁL, Giraldo P, Abarca-Lachen E, Surra JC, Osada J, Hamilton KL, Raychaudhuri SP, Marigil M, Juarranz Á, Wulff H, Miura H, Gilaberte Y, Köhler R.

PLoS One. 2020 Mar 9;15(3):e0222619. doi: 10.1371/journal.pone.0222619. eCollection 2020.

2.

Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDSs) for senicapoc.

Buya AB, Ucakar B, Beloqui A, Memvanga PB, Préat V.

Int J Pharm. 2020 Mar 3;580:119180. doi: 10.1016/j.ijpharm.2020.119180. [Epub ahead of print]

PMID:
32135227
3.

Synthesis of Small-Molecule Fluorescent Probes for the In Vitro Imaging of Calcium-Activated Potassium Channel KCa 3.1.

Brömmel K, Maskri S, Maisuls I, Konken CP, Rieke M, Pethő Z, Strassert CA, Koch O, Schwab A, Wünsch B.

Angew Chem Int Ed Engl. 2020 Feb 25. doi: 10.1002/anie.202001201. [Epub ahead of print]

PMID:
32097518
4.

KCa3.1 channel blockade attenuates microvascular remodelling in a large animal model of bleomycin-induced pulmonary fibrosis.

Derseh HB, Dewage SNV, Perera KUE, Pagel CN, Koumoundouros E, Organ L, Snibson KJ.

Sci Rep. 2019 Dec 27;9(1):19893. doi: 10.1038/s41598-019-56412-z.

5.
6.

Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Roach KM, Bradding P.

Br J Pharmacol. 2020 Mar;177(5):1003-1024. doi: 10.1111/bph.14939. Epub 2020 Feb 3. Review.

PMID:
31758702
7.

Dehydrated hereditary stomatocytosis: clinical perspectives.

Frederiksen H.

J Blood Med. 2019 Jul 4;10:183-191. doi: 10.2147/JBM.S179764. eCollection 2019.

8.

Erythrocyte ion content and dehydration modulate maximal Gardos channel activity in KCNN4 V282M/+ hereditary xerocytosis red cells.

Rivera A, Vandorpe DH, Shmukler BE, Andolfo I, Iolascon A, Archer NM, Shabani E, Auerbach M, Hamerschlak N, Morton J, Wohlgemuth JG, Brugnara C, Snyder LM, Alper SL.

Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C287-C302. doi: 10.1152/ajpcell.00074.2019. Epub 2019 May 15.

PMID:
31091145
9.

Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease.

Jin LW, Lucente JD, Nguyen HM, Singh V, Singh L, Chavez M, Bushong T, Wulff H, Maezawa I.

Ann Clin Transl Neurol. 2019 Mar 18;6(4):723-738. doi: 10.1002/acn3.754. eCollection 2019 Apr.

10.

KCa3.1 Transgene Induction in Murine Intestinal Epithelium Causes Duodenal Chyme Accumulation and Impairs Duodenal Contractility.

Valero MS, Ramón-Gimenez M, Lozano-Gerona J, Delgado-Wicke P, Calmarza P, Oliván-Viguera A, López V, Garcia-Otín ÁL, Valero S, Pueyo E, Hamilton KL, Miura H, Köhler R.

Int J Mol Sci. 2019 Mar 8;20(5). pii: E1193. doi: 10.3390/ijms20051193.

11.

Intestinal epithelial potassium channels and CFTR chloride channels activated in ErbB tyrosine kinase inhibitor diarrhea.

Duan T, Cil O, Thiagarajah JR, Verkman AS.

JCI Insight. 2019 Feb 21;4(4). pii: 126444. doi: 10.1172/jci.insight.126444. eCollection 2019 Feb 21.

12.

Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion.

Torriani G, Trofimenko E, Mayor J, Fedeli C, Moreno H, Michel S, Heulot M, Chevalier N, Zimmer G, Shrestha N, Plattet P, Engler O, Rothenberger S, Widmann C, Kunz S.

J Virol. 2019 Mar 5;93(6). pii: e01744-18. doi: 10.1128/JVI.01744-18. Print 2019 Mar 15.

13.

Drugs for preventing red blood cell dehydration in people with sickle cell disease.

Nagalla S, Ballas SK.

Cochrane Database Syst Rev. 2018 Oct 19;10:CD003426. doi: 10.1002/14651858.CD003426.pub6.

14.

Topical Delivery of Senicapoc Nanoliposomal Formulation for Ocular Surface Treatments.

Phua JL, Hou A, Lui YS, Bose T, Chandy GK, Tong L, Venkatraman S, Huang Y.

Int J Mol Sci. 2018 Sep 29;19(10). pii: E2977. doi: 10.3390/ijms19102977.

15.

Activation mechanism of a human SK-calmodulin channel complex elucidated by cryo-EM structures.

Lee CH, MacKinnon R.

Science. 2018 May 4;360(6388):508-513. doi: 10.1126/science.aas9466.

16.

Sickle cell dehydration: Pathophysiology and therapeutic applications.

Brugnara C.

Clin Hemorheol Microcirc. 2018;68(2-3):187-204. doi: 10.3233/CH-189007.

PMID:
29614632
17.

KCa3.1 channel inhibition leads to an ICAM-1 dependent increase of cell-cell adhesion between A549 lung cancer and HMEC-1 endothelial cells.

Bulk E, Kramko N, Liashkovich I, Glaser F, Schillers H, Schnittler HJ, Oberleithner H, Schwab A.

Oncotarget. 2017 Nov 28;8(68):112268-112282. doi: 10.18632/oncotarget.22735. eCollection 2017 Dec 22.

18.

A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis.

Roach KM, Sutcliffe A, Matthews L, Elliott G, Newby C, Amrani Y, Bradding P.

Sci Rep. 2018 Jan 10;8(1):342. doi: 10.1038/s41598-017-18555-9.

19.

Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease.

Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P.

World J Gastroenterol. 2017 Jun 21;23(23):4181-4190. doi: 10.3748/wjg.v23.i23.4181.

20.

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.

Brown BM, Pressley B, Wulff H.

Curr Neuropharmacol. 2018;16(5):618-626. doi: 10.2174/1570159X15666170630164226.

Supplemental Content

Loading ...
Support Center